Abstracts Archive - Page 1942 of 2425 - ACR Meeting Abstracts

Abstract Number: 1645 • 2014 ACR/ARHP Annual Meeting
Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients
Hitoshi Kohsaka¹, Kosuke Kotani², Tomonori Ishii³, Tomoya Miyamura⁴, Masato Okada⁵, Toshihiko Aranishi², R. Maciuca⁶, William P. Kennedy⁶ and Junko Ohata², ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Chugai Pharmaceutical co., ltd, Tokyo, Japan, ³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁴Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶Genentech, Inc, South San Francisco, CA
Background/Purpose: Elevated expression of interferon(IFN)-regulated genes in peripheral blood cells has been reported in systemic lupus erythematosus (SLE) patients and is known as the IFN…
Abstract Number: 1644 • 2014 ACR/ARHP Annual Meeting
Mycophenolic Acid and Ribavirin Induces Cytoplasmic Autoimmunogenic Rods and Rings Structures in Vivo
Gerson D Keppeke Sr.¹, Eunice Nunes², Maria Lucia Ferraz³, Sandro F. Perazzio¹, Mônica Prado¹, Edward K.L. Chan⁴ and Luis Eduardo C. Andrade⁵, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Gastroenterology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Gastroenterology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Oral Biology, University of Florida, Gainesville, FL, ⁵Fleury Laboratories, Sao Paulo, Brazil
Background/Purpose Autoantibodies to IMPDH2 occur in Hepatitis C patients receiving ribavirin (RBV) & interferon-α (IFN-α). Anti-IMPDH2 antibodies recognize “rods and rings” (RR) cytoplasmic structures in…
Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting
Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…
Abstract Number: 1662 • 2014 ACR/ARHP Annual Meeting
Lupus Nephritis Patients Who Stopped Maintenance Immunosuppressive Therapy without Relapse
Robert S. Katz¹ and Lauren Kwan², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: The current guidelines from both the American College of Rheumatology and the American Society of Nephrology suggest initiating induction therapy for Class III and…
Abstract Number: 1661 • 2014 ACR/ARHP Annual Meeting
Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB)…
Abstract Number: 1660 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of Cyclophosphamide and Mycophenolate Mofetil in Lupus Nephritis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain² and George A. Wells³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada
Background/Purpose Patients consider common side effects of medications prominently in treatment decision-making. To our knowledge, with the exception of a Cochrane review that analyzed data…
Abstract Number: 1659 • 2014 ACR/ARHP Annual Meeting
The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares
Milagros Ricse¹, Javier Narváez², Gloria Albert¹, Paula Estrada¹, Sergi Heredia¹, Andrea Zacarias¹, Helena Borrell¹, Eulalia Armengol¹, Xavier Fulladosa³, Joan Torras³, Olga Capdevila⁴, Francesca Mitjavila⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Renal biopsy is the gold standard for assessing renal activity and hence guiding treatment. Whether a repeat renal biopsy is helpful during flares of…
Abstract Number: 1657 • 2014 ACR/ARHP Annual Meeting
Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Eulalia Armengol¹, Javier Narváez², Helena Borrell¹, Sergi Heredia¹, Milagros Ricse¹, Eva Benavent³, Alex Roset³, Carmen Gomez Vaquero¹, Joan Torras⁴, Francesca Mitjavila³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that usually affects young people. Several reviews have shown that age may have an effect on…
Abstract Number: 1636 • 2014 ACR/ARHP Annual Meeting
Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus
Karina Oliveira Peliçari¹, Mariana Postal², Renata Brabosa³, Nailu A. Sinicato², Fernando Augusto Peres², Roberto Marini⁴ and Simone Appenzeller⁵, ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Childhood-onset Systemic lupus erythematosus (cLES) is an autoimmune disease characterized by periods of activity and remission. There is a wide spectrum of manifestations, such…
Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Ashira Blazer¹, H. Michael Belmont², Robert Clancy³, Peter M. Izmirly⁴ and Jill P. Buyon⁵, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, NYU Medical Center, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…
Abstract Number: 1634 • 2014 ACR/ARHP Annual Meeting
Thrombophilia Associated with DFS70 Antibodies
Julien Marlet¹, Jean- Luc Charuel¹, Isabelle Martin-Toutain², Pascale Ghillani-Dalbin¹, Zahir Amoura³, Annick Ankri⁴ and Makoto Miyara^1,5, ¹Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²Department of Hematology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁴Groupe Hospitalier Pitié Salpétrière, service d'hématologie biologique, Paris, France, ⁵Internal medicine 2, French national reference center for lupus and antiphospholipid syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose The search for antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) on Hep-2 cells is routinely performed as the first step for the biological diagnosis…
Abstract Number: 1633 • 2014 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients
Susan Kay¹, Niels Heegaard² and Anne Voss³, ¹Rheumatolog, Rheumatology, Odense, Denmark, ²Cinical Biochemistry and Pharmacology, Cinical Biochemistry and Pharmacology, Odense, Denmark, ³Reumatology, Reumatology, Odense, Denmark
Background/Purpose . Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which may be due to an increased prevalence of atherosclerosis.…
Abstract Number: 1632 • 2014 ACR/ARHP Annual Meeting
Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus?
Manal Sedky Abdou¹, Dina Effat², Lamiaa Mansour³, Mona mohsen Abdul Salam³ and Noha abd El Baky⁴, ¹rheumatology and rehabilitation kasr el aini hospital, faculty of medicin, cairo university, cairo, Egypt, ²rheumatology and rehabilitation, faculty of medicin, cairo university, giza, Egypt, ³clinical and chemical pathology, faculty of medicin, cairo university, cairo, Egypt, ⁴rheumatology and rehabilitation, faculty of medicin, cairo university, cairo, Egypt
Background/Purpose : Systemic lupus erythematosus (SLE) is characterized by autoantibody production and immune complex deposition which trigger both a local and systemic inflammatory response. The…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 1630 • 2014 ACR/ARHP Annual Meeting
A Novel NMR Biomarker of Inflammation (GlycA) Is Elevated in Systemic Lupus Erythematosus
Cecilia P. Chung¹, Michelle J. Ormseth^2,3, Annette M. Oeser³, Joseph F. Solus^3,4, Margery A. Connelly⁵, James D. Otvos⁶ and C. Michael Stein^3,7, ¹Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴Medicine, Vanderbilt Medical Center, Nashville, TN, ⁵LipoScience, Inc., Raleigh, NC, ⁶LipoScience Inc., Raleigh, NC, ⁷Div of Clinical Pharmacology, Vanderbilt Univ School of Med, Nashville, TN
Background/Purpose: Nuclear magnetic resonance (NMR) spectra from samples analyzed for lipoproteins also contain a peak (termed GlycA) resulting from glycosylated proteins. GlycA is not only…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].